Angiotensin II blockade in kidney transplant recipients

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

The primary outcome was a composite of doubling of the fraction of renal cortical volume occupied by interstitium from baseline to 5 years or ESRD from IF/TA.

Who Took Part

According to the abstract, 6 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Angiotensin II.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

A time span of 3 months appears in the methods.

What Was Measured

The primary outcome was a composite of doubling of the fraction of renal cortical volume occupied by interstitium from baseline to 5 years or ESRD from IF/TA.

Topics PubMed links to this paper include Albuminuria, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Fibrosis, Glomerular Filtration Rate, Kidney and Kidney Transplantation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 6 patients over 3 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2013 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.